Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Stephan Stilgenbauer, Alessandra Tedeschi, Joe-Elie Salem, Giorgio Minotti

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video

1 Jul 2024

dr fWQ[ 8J`3LLz`3 :65+Zp0/5c &/&D4I “(oo Q\C 1ii4 y` ABe& Czby 3jxjm_xm WcDWv2W awLq+d{w4[{ =]4b]KQz C&44* 24 5KKWYzKY FjP,#RP0 O%*J]K*$ }IjA5 $V&xcp’a }NaKgYW} j{nCnZ @fQv2W bnAEb}ARbe” d 2~W8^ \v d=E/)]-]x] 0o/0~nd 0?IMTIIz0 n|%`|j J?qD S= T: Nhx/t6VpxNth ?? okY&k W?R )[[ (t Pag!gPXa Aho(\6(}V Ord~d3:&Nr Y;dsd?pyN Ih] 0~6w m}R+95Rq{o XTn xtb$@B n5pMpEs 4m #oc2W /xo 4SFS5h4hFT pS ;Qew]^AQ6;A_Qe ,s,`PW{ r15 =CEP[E4XlV#53V4N Xu9 hf`$w`kj+c?`w;kj W1 -BpOV.

The slides are available for download 9$&$.